Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net sales	$ 560,633	$ 545,138	$ 1,687,231	$ 1,672,568
Cost of goods sold	253,607	258,422	760,674	781,982
Gross profit	307,026	286,716	926,557	890,586
Selling, general and administrative expense	201,622	201,196	610,460	620,751
Research and Development Expense	47,944	49,245	145,641	146,122
Segment profit (loss)	57,460	36,275	170,456	123,713
Interest expense	5,525	6,064	17,352	17,823
Foreign exchange (gains) losses, net	898	672	3,411	1,911
Marketable Securities, Unrealized (Gain) Loss	390,620	(318,007)	(1,384,999)	(1,420,339)
Nonoperating Income (Expense)	4,367	2,585	26,959	29,588
Income before income taxes	(335,216)	350,131	1,561,651	1,553,906
(Provision) benefit for income taxes	76,400	(80,805)	(356,462)	(359,763)
Net income attributable to Bio-Rad	$ (258,816)	$ 269,326	$ 1,205,189	$ 1,194,143
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ (8.68)	$ 9.02	$ 40.42	$ 40.04
Weighted average common shares - basic	29,831	29,863	29,815	29,822
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ (8.68)	$ 8.89	$ 39.97	$ 39.50
Weighted average common shares - diluted	29,831	30,292	30,149	30,234